XNAS
NAII
Market cap14mUSD
Jul 09, Last price
2.24USD
1D
-1.75%
1Q
-20.95%
Jan 2017
-80.18%
Name
Natural Alternatives International Inc
Chart & Performance
P/E
—
P/S
0.11
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-2.34%
Rev. gr., 5y
1.78%
Revenues
130m
+14.12%
Net income
-14m
L+88.10%
CFO
6m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Natural Alternatives International, Inc. (NAII) is a company dedicated to the global development, manufacturing, and marketing of nutritional supplements, with operations spanning the United States, Europe, Asia, and other international territories. The company functions through two main divisions: Private-Label Contract Manufacturing and Patent and Trademark Licensing. Through its contract manufacturing segment, NAII provides tailored production services to businesses that market and distribute a range of health-related products, including vitamins, minerals, herbal remedies, and other dietary supplements. NAII also offers extensive strategic partnering support, which encompasses a broad spectrum of services. These include research and development (such as customized product formulation, scientific research, and proprietary ingredients), clinical studies, manufacturing, marketing assistance, adherence to international regulatory and labeling laws, global product registration, diverse packaging and labeling design, product testing, evaluation, and overall regulatory review. Furthermore, the company markets its own proprietary beta-alanine ingredient, available under the brand names CarnoSyn and SR CarnoSyn. NAII produces its supplements in various formats, including capsules, tablets, chewable wafers, and powders. Its private-label manufacturing clients primarily consist of companies distributing nutritional supplements through direct sales networks, direct-to-consumer e-commerce platforms, and traditional retail stores. Natural Alternatives International, Inc. was established in 1980 and is based in Carlsbad, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||